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ABSTRACT
Effective treatment of advanced metastatic disease remains the primary 
challenge in the management of inoperable pancreatic cancer. Current therapies such 
as oxaliplatin (OxPt)-based chemotherapy regimens (FOLFIRINOX) provide modest 
short-term survival improvements, yet with significant toxicity. Photodynamic therapy 
(PDT), a light-activated cancer therapy, demonstrated clinical promise for pancreatic 
cancer treatment and enhances conventional chemotherapies with non-overlapping 
toxicities. This study investigates the capacity of neoadjuvant PDT using a clinically-
approved photosensitizer, benzoporphyrin derivative (BPD, verteporfin), to enhance 
OxPt efficacy in metastatic pancreatic cancer. Treatment effects were evaluated in 
organotypic three-dimensional (3D) cultures, clinically representative models that 
bridge the gap between conventional cell cultures and in vivo models. The temporally-
spaced, multiparametric analyses demonstrated a superior efficacy for combined 
PDT+OxPt compared to each monotherapy alone, which was recapitulated on different 
organotypic pancreatic cancer cultures. The therapeutic benefit of neoadjuvant PDT 
to OxPt chemotherapy materialized in a time-dependent manner, reducing residual 
viable tissue and tumor viability in a manner not achievable with OxPt or PDT alone. 
These findings emphasize the need for intelligent combination therapies and relevant 
models to evaluate the temporal kinetics of interactions between mechanistically-
distinct treatments and highlight the promise of PDT as a neoadjuvant treatment for 
disseminated pancreatic cancer.
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INTRODUCTION
Advanced pancreatic cancer is a lethal malignancy 
for which the late diagnosis and limited effective treatment 
options yield 5-year survival rates below 5% [1]. Standard 
palliative care of advanced inoperable pancreatic cancer 
involves systemic gemcitabine, which achieves median 
patient survival to 5.6 months post-diagnosis [2]. Advances 
in chemotherapeutic approaches have seen modest success 
in large placebo-controlled clinical trials [2, 3], the most 
effective being FOLFIRINOX, a stringent chemotherapy 
cocktail comprising folinic acid, 5-fluorouracil, irinotecan, 
and oxaliplatin (OxPt) [1]. However, the high toxicity of 
FOLFIRINOX renders only patients with high performance 
scores eligible for this regimen [1, 4]. These statistics 
illustrate the need for more effective and less toxic treatment 
strategies for pancreatic cancer. Intelligently designed 
combination therapies may be crucial to overcome treatment 
resistance and improve survival, in part by reducing tumor 
burdens to make more patients eligible for surgery [5]. 
                                                       Research Paper
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Recent studies have demonstrated the potential 
of photodynamic therapy (PDT) for the treatment of 
pancreatic cancer. PDT for internal solid tumors comprises 
the systemic administration of a photosensitizing agent 
that diffuses into the tumor tissue. Subsequent irradiation 
of the tumor tissue with non-toxic laser light excites the 
photosensitizer to generate highly cytotoxic reactive 
molecular species at the tumor site. Tumor tissues are 
consequently eradicated through excessive oxidative 
damage, shutdown of the tumor vasculature, hypoxia, 
hyponutrition, and an anti-tumor immune response [6, 7]. 
In vitro, PDT was highly effective against chemoresistant 
pancreatic cancer cells [8], and adjuvant PDT was shown 
to reduce pancreatic cancer dissemination and enhance the 
efficacy of irinotecan and cabozantinib as a neoadjuvant 
therapy in orthotopic xenograft mouse models [9, 10]. 
A recent phase I/II clinical trial demonstrated that 
PDT was feasible and safe for the (adjuvant) treatment 
of inoperable pancreatic cancer patients, achieving a 
median patient survival of 8 months [11]. Importantly, 
a remarkable reduction in tumor volume following PDT 
rendered a single inoperable patient eligible for surgery, 
as the shrinkage of the tumor volume resulted in the 
superior mesenteric artery to be no longer enveloped by 
the malignancy [11]. These results demonstrate that PDT 
is feasible for clinical application as a (neo)adjuvant 
therapy for pancreatic cancer patients, and that its unique 
therapeutic mechanism may synergize with conventional 
chemotherapies for this disease. An unanswered question 
of critical importance remains the capacity of PDT to 
enhance treatment responses for disseminated pancreatic 
cancer metastases. 
For investigations towards new treatments and 
their expedited clinical translation, 3D culture models of 
cancer are gaining appreciation and are being increasingly 
utilized. These models recapitulate the architecture 
and heterogeneity of tumors with more accuracy than 
conventional 2D cell cultures [12], yet still retain high-
throughput in comparison to in vivo models [13]. For 
pancreatic cancer specifically, various studies have 
employed 3D culture models for a range of investigations 
[14], including mechanisms of oncogenic transformation 
[15], redox metabolism in response to treatment [16], 
effects of stromal components and extracellular matrix 
rigidity on treatment response [17], and to recapitulate 
tumor heterogeneity and perform therapeutic screening 
[18]. Thus, 3D culture models represent a multifunctional 
preclinical platform that bridge the gap between in vitro 
and in vivo experimentation [12].
In the current study, we leverage established 3D 
culture methods and a recently developed treatment 
analysis methodology [19] to model micrometastatic 
pancreatic cancer and investigate the potential of a 
combination therapy that comprises PDT and subsequent 
OxPt chemotherapy. The current study builds on the 
demonstrated ability of PDT to overcome chemoresistance 
and synergize with conventional cancer treatments, 
including platinum-based chemotherapies [20–22]. The 
primary goals were to establish whether neoadjuvant PDT 
could augment the efficacy of OxPt chemotherapy and 
whether PDT can prevent tumor recovery in 3D-cultures for 
micrometastatic pancreatic cancer. The results of this study 
demonstrate that the intrinsic chemotherapy resistance of 
AsPC-1 micrometastatic pancreatic cancer organoids can be 
overcome with neoadjuvant PDT, and that this combination 
therapy may hold potential in reducing the viability and 
extent of residual disease of micrometastatic pancreatic 
cancer.
RESULTS
Growth characteristics of 3D cultures comprising 
primary and metastatic pancreatic cancer cells
To model micrometastatic pancreatic cancer 
in vitro, we applied established protocols for 3D adherent 
cultures on solidified Matrigel scaffolds [21, 23] to 
grow tumor organoids from metastatic AsPC-1 human 
pancreatic cancer cells. To assess the effects of treatment 
on 3D cultures and optimize the treatment schedules, it 
is imperative to first characterize the growth behavior of 
such cultures. 
The general growth features of AsPC-1 organoids 
were investigated and compared to organoid cultures 
comprising MIA PaCa-2 cells. As specified by the 
American Type Culture Collection, AsPC-1 cells are 
derived from the ascites of a 62-year-old female with 
pancreatic cancer, whereas the epithelial MIA PaCa-
2 cells originate from the primary pancreatic tumor of a 
65-year old male [24]. In 3D adherent cultures, the cell 
lines exert clear phenotypic differences (Figure 1A, 1B); 
it was observed that AsPC-1 cells form substantially smaller 
organoids compared to organoids composed of MIA PaCa-
2 cells. Necrotic cores within individual tumor organoids 
were typically absent in AsPC-1 organoids (Figure 1A), yet 
frequently observed in the MIA PaCa-2 cultures (Figure 1B). 
Organoid growth curves (Figure 1C) illustrate that MIA 
PaCa-2 tumors expand at a significantly higher rate 
(P < 0.05), corresponding to higher proliferation rates and 
cell numbers in these cultures (Supplementary Figure 1). 
Organoid size distributions of both cultures measured 
11 days after culture initiation are depicted in Figure 1D 
and reveal that organoid sizes of AsPC-1 and MIA PaCa-
2 cultures are not normally distributed (D’Agostino & 
Pearson-Omnibus test p < 0.0001 for both distributions). 
Non-parametrical statistical analysis showed that AsPC-
1 organoids were significantly smaller compared to 
MIA PaCa-2 organoids (median size 4.0*103 µm2 vs 
1.1*104 µm2, p < 0.001, Mann-Whitney U-test). This was 
recapitulated in separate experiments that compared the 
growth and size-distributions of MIA PaCa-2, AsPC-1, 
which additionally included 3D cultures of PANC-1 human 
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primary pancreatic carcinoma cells (Supplementary Figure 
2). Lastly, the viability of untreated AsPC-1 organoids was 
higher and less heterogeneously distributed compared to 
the viabilities of untreated MIA PaCa-2 organoid cultures, 
which is attributed to the absence of necrotic cores in the 
AsPC-1 cultures (Figure 1E). Taken together, the results 
demonstrate clear variations in tumor growth rates and 
baseline viabilities, emphasizing the need to normalize 
organoid size and viabilities to compare treatment effects 
between cultures of different cell types. 
The growth and size characteristics of organoid 
cultures are relevant with respect to drug diffusion 
and treatment efficacy in cancer organoids. Previous 
investigations have demonstrated that platinum-based 
chemotherapeutics are capable of diffusing throughout 
entire organoids with higher concentrations at the organoid 
peripheries [25, 26]. However, studies on ovarian cancer 
organoids showed that there was a correlation between 
nodule size and cisplatin efficacy [27]. With respect to 
PDT, previous studies have demonstrated that BPD has a 
limited diffusion range that was sufficient to completely 
photosensitize small organoids, yet photosensitization 
was restricted to the periphery of larger organoids [28]. 
Thus, the organoid size may be inversely correlated to 
sensitivity to both platinum-based chemotherapeutics 
and BPD-PDT, emphasizing that a characterization of 
tumor nodule growth may potentially explain differences 
in treatment susceptibility between organoid cultures of 
different cytologic origin.
Pancreatic cancer organoids comprising cells 
of metastatic origin are resistant to OxPt 
chemotherapy
As FOLFIRINOX constitutes one of the major 
types of palliative therapy for advanced metastatic cancer, 
we compared the susceptibility of the micrometastatic 
pancreatic cancer model (AsPC-1 organoids) and the 
primary tumor model (MIA PaCa-2 organoids) to OxPt, 
a core component of the FOLFIRINOX regimen. The 
experimental timeline for the OxPt dose-escalation 
experiment is depicted in Figure 2A. The live/dead 
fluorescence microscopy images and the corresponding 
viability heatmaps are shown for AsPC-1 and MIA PaCa-
2 organoids in Figure 2B and 2C, respectively. 
With respect to organoid area, OxPt exerted a slight 
dose-dependent decrease in size of the MIA PaCa-2 
organoids that was not observed in the AsPC-1 cultures 
Figure 1: Masked brightfield images illustrate the overall size and spacing of the tumor organoids of AsPC-1 (A) and MIA PaCa-2 
(B) cultures. Cultures were stained for live (calcein AM, green) and dead (PI, red) cells to reveal the presence of necrotic cores in the 3D 
cultures (live/dead panels) in absence of treatment on days 11 and 15. Scalebar = 400 µm. (C) Growth of AsPC-1 (green) and MIA PaCa-2 
(blue) organoids (mean ± 95% CI, N = 3000–8000). (D) Size distributions of individual AsPC-1 (green) and MIA PaCa-2 (red) organoids 
on day 11, in µm2. (E) Distributions of organoid viability of AsPC-1 organoids (green) and MIA PaCa-2 organoids (blue) on culture day 11. 
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(Figure 2D). With respect to the viability, MIA PaCa-2 
organoids were significantly more susceptible to OxPt 
compared to AsPC-1 (Figure 2E). Whereas the OxPt 
IC50 was fitted at 646 µM for MIA PaCa-2 organoid 
cultures under the given exposure conditions, the IC50 
for AsPC-1 organoid cultures was >1 mM. Analysis of 
the cumulative residual viable disease per well following 
OxPt chemotherapy demonstrates that despite its ability 
to decrease viability, OxPt chemotherapy is inefficient in 
reducing the residual viable disease left within the cultures 
(Figure 2F). This parameter also demonstrates that AsPC-
1 organoids are less affected by OxPt chemotherapy 
than the MIA PaCa-2 organoids, albeit to a minor extent 
and reaching significance only at a dose of 500 µM. 
Taken together, the results clearly demonstrate that the 
micrometastatic pancreatic cancer organoids are more 
resistant to OxPt chemotherapy in comparison to primary 
tumor organoids. The distribution of viability throughout 
the organoids suggest a homogeneous diffusion of OxPt 
throughout the organoids, thus corroborating previous 
findings [25, 26]. We identified negative correlations 
between organoid size and oxaliplatin sensitivity in both 
culture types for various concentrations, demonstrating 
that larger organoids were more susceptible to OxPt 
chemotherapy (Figure 2E–2I). This contradicts previous 
investigations that demonstrated a positive correlation 
between organoid size and cisplatin susceptibility in 
ovarian cancer models [27]. Our findings demonstrate 
reduced OxPt efficacy in AsPC-1 organoids compared 
to MIA PaCa-2 organoids even in nodules of comparable 
sizes (Figure 2E–2I), indicating that organoid size 
alone does not account for the OxPt resistance in AsPc-
1 nodules. The potential origins of resistance were 
not further explored in this study, but may potentially 
be caused by alterations in adhesive and metabolic 
phenotypes [29, 30], two factors that have been implicated 
in treatment recalcitrance [30, 31]. 
Neoadjuvant low-dose PDT acutely reduces 
residual viable disease following OxPt 
chemotherapy
Various investigations have shown that PDT can 
overcome chemotherapy resistance in preclinical models 
[8, 9, 32–34]. To ascertain whether the efficacy of OxPt 
could be increased with neoadjuvant PDT, the OxPt 
dose-escalation experiment as depicted in Figure 2 was 
repeated, but with PDT performed immediately prior to 
treatment with OxPt (Figure 3A). A PDT regimen of 0.25 
µM BPD (90 min photosensitization period) and 690 nm 
laser light irradiation at a radiant exposure of 10 J/cm2 
(50 mW/cm2) was chosen as this roughly equated to an 
IC10 dose in terms of residual cumulative viable disease 
(Figure 3E). 
There were no discernable effects of OxPt alone or 
the combination therapy on organoid size as determined 
using brightfield microscopy (Figure 3B). Viability was 
not affected by PDT alone (Figure 3E), but dropped 
significantly upon subsequent exposure to OxPt (Figure 
3C), even at low OxPt doses. Approximations of IC50 
values using the viability dose-response data were highly 
ambiguous. There was a dose-response correlation upon 
exposure to concentrations >100 µM, and viabilities were 
significantly lower in the PDT+OxPT treated groups 
compared to the groups receiving equimolar concentrations 
of OxPt alone, especially at lower OxPt doses (Figure 3E). 
The cumulative viable disease was significantly reduced by 
PDT alone, and the reduction was substantially enhanced 
by OxPt (Figure 3D and 3F). Based on the residual viable 
disease, the IC50 for OxPt alone could not be accurately 
estimated, but for PDT+OxPt the IC50 was approximated 
to 5.05 µM. It should be noted that the extent of viable 
disease was not reduced beyond 37% (bottom plateau). 
The adjuvant effect of PDT is best observed at the 
highest OxPt dose, where PDT+1000 µM OxPt reduced 
the median cumulative viable disease by 77.8% versus 
30.0% by chemotherapy alone (P < 0.005) (Figure 3F). In 
contrast to the negative size-response correlation for OxPt, 
there was a positive correlation between organoid size and 
susceptibility to PDT that indicates that smaller organoids 
are significantly more susceptible to BPD-PDT compared 
to their larger counterparts. (Figure 3G). Importantly, these 
size-dependent responses to OxPt and PDT were lost in 
AsPC-1 cultures exposed to the combination therapy 
(Figure 3G). Thus, neoadjuvant PDT exerts a significant 
beneficial effect on the OxPt chemotherapy efficacy by 
mildly reducing overall organoid, reducing the extent of 
residual viable disease, and overcoming size-dependent 
susceptibilities. 
We additionally explored whether the beneficial 
effects of neoadjuvant PDT on OxPt efficacy could be 
recapitulated on MIA PaCa-2 and PANC-1 organoid 
cultures. Early findings in 3D cultures of PANC-1 cells 
corroborate the findings observed in the AsPC-1 cultures, 
where low-dose PDT (2.5 J/cm2) significantly reduced 
residual viable disease following OxPt chemotherapy 
(1 µM, 72 h exposure) (Supplementary Figure 3). 
Moreover, there was a sequence-dependent interaction 
between OxPt and PDT; PDT performed before OxPt 
chemotherapy was significantly more effective than OxPt 
exposure before PDT (Supplementary Figure  3C), thereby 
corroborating previous findings on micrometastatic 
ovarian cancer organoids [21]. Results on MIA PaCa-
2 organoids demonstrate that low-dose PDT (10 J/cm2) 
also exerted a significant beneficial effect on 100 µM 
OxPt exposure. These were evident upon assessment of 
residual viable disease, but not by evaluating organoid 
viability (Supplementary Figure  4). In conclusion, 
despite differences in treatment susceptibility in various 
cell lines, the beneficial effects of neoadjuvant PDT on 
OxPt chemotherapy efficacy can be recapitulated in 
various organoid cultures of pancreatic cancer cell lines, 
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corroborating findings on combined PDT with carboplatin 
for treatment of ovarian cancer organoids [21].
Prolonged efficacy of OxPt chemotherapy is 
augmented by neoadjuvant sublethal PDT 
Cancer relapse is frequently observed in pancreatic 
cancer patients following chemotherapy and is a 
major cause of mortality [35]. To investigate whether 
neoadjuvant PDT could prevent tumor regrowth, the 
OxPt dose response experiment was repeated with and 
without neoadjuvant PDT, after which the cultures were 
maintained in the absence of treatments for another week. 
On culture day 18, the experiments were terminated and 
the health of the cultures was assessed (Figure 4A). 
Although median organoid sizes did not follow 
a dose-response correlation, organoids treated with 
PDT+OxPt appeared to be smaller in size compared to 
organoids treated with OxPt alone (Figure 4B), which 
is supported by similar findings in other tumor models 
Figure 2: Comparison of OxPt treatment effects between AsPC-1 an d MIA PaCa-2 organoid cultures. (A) Schematic 
representation of the experiment timeline. Live/dead fluorescence overlays and viability heatmaps of AsPC-1 organoids (B) and MIA 
PaCa-2 organoids (C) treated with OxPt. Scalebar = 400 µm. (D) Dose response curves based on the normalized median organoid size. 
(Mean ± SEM, N = 36). (E) Dose response curves based on the median viability of the organoid cultures. (Mean ± stdev N = 36). (F) Dose 
response curves based on the normalized cumulative viable area (Mean ± SEM, N = 9). (G–I) Scatter plots of organoid area and organoid 
viability following OxPt therapy on AsPC-1 (black) and MIA PaCa-2 (green) organoids. Size-response plots are depicted for the (G) 
100 µM OxPT treatment, (H) 500 µM OxPt treatment, and (I) 1000 µM OxPt treatment. Significant size-response correlations are depicted 
in the image as determined using a Spearman’s ranked correlation test, displaying the Spearman coefficient r and the p-value for each data 
set (ns = not significant). For each data set, the first 1000 nodules are displayed within a single representative experiment.
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[13, 36]. In terms of viability (Figure 4C), neoadjuvant 
PDT significantly enhanced the efficacy of OxPt 
chemotherapy. In combination with PDT, the OxPt IC50 
was reduced from 1695 µM (95% CI: 735.7 to 3905 µM) 
to 66.95 µM (95% CI: 28.88 to 180.1 µM), representing 
a 25-fold enhancement in OxPt efficacy (P < 0.0001). 
PDT extensively reduced the extent of residual viable 
disease (Figure 4D), an effect that was further augmented 
by subsequent OxPt exposure. The fitted dose response 
curve for PDT+OxPt was significantly different from 
that of OxPt alone (P < 0.0001). Based on the residual 
viable disease, the IC50 of OxPt was 23.55 µM for the 
single therapy and 4.64 µM for the combination therapy 
PDT+OxPt. This relatively modest decrease in IC50 
(5.1-fold efficacy enhancement) can be explained by 
the plateau in residual viable disease of OxPt alone; the 
bottom of the curve was at 0.49 of OxPt alone whereas 
it was at 0.12 for PDT+OxPt. Similarly to the results 
obtained on day 11 (Figure 3), larger organoids were less 
affected by PDT compared to their smaller counterparts, 
but there was no significant size-dependent response 
for the OxPt or the PDT+OxPt treatments (Figure 4G). 
Thus, PDT substantially enhances the OxPt efficacy 
by significantly reducing both organoid viability and 
cumulative viable disease on the long term, regardless of 
organoid size. 
As a single therapy, PDT significantly reduced the 
viability of the AsPC-1 organoid cultures, giving rise 
to a heterogeneous mix of highly viable and non-viable 
organoids (Figure 4E, purple). Additional exposure to 
OxPt resulted in a more homogeneous distribution in 
viability, indicating that OxPt enhances PDT efficacy 
by reducing heterogeneity between organoids within 
the same culture. This heterogeneity is recapitulated 
when looking at the viable organoid area (Figure 4F). 
PDT as a single therapy yields a highly-dispersed range 
Figure 3: Comparison of immediate dose response effects of OxPt as a single therapy (black, same as Figure 2) or with 
neoadjuvant PDT (green) on AsPC-1 organoid cultures. (A) Schematic overview of the experiment timeline. (B) Dose response 
curves based on the normalized organoid area (Mean ± stdev, N = 36). (C) Dose response curves based on the viability of the organoid 
cultures (Mean ± stdev, N = 36). (D) Dose response curves based on the cumulative viable area (Mean ± SEM, N = 9). Box-whisker plots 
depicting the medians, the 25th and 75th percentiles, and the 95% confidence interval of (E) the organoid viability (N = 36) and (F) the 
organoid live area per image (N = 36). (G) Scatter plots of organoid area and organoid viability following 500 µM OxPt (black), 10 J/cm2 
BPD-PDT (red), and OxPt+PDT (green). Significant size-response correlations are depicted in the image as determined using a Spearman’s 
ranked correlation test, displaying the Spearman coefficient r and the p-value for each data set (ns = not significant). For each data set, the 
first 1000 nodules are displayed within a single representative experiment.
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in the viable area of the organoids, which is strongly 
reduced upon subsequent OxPt exposure, even at low 
doses (e.g., 1–100 µM). Importantly, the PDT-OxPt 
combination therapy achieved near-complete eradication 
of the cultures at relatively low OxPt doses (100 µM), 
whereas 10-fold higher doses of OxPt alone left a 
substantial amount of residual viable disease. Together, 
the results unequivocally show that a combination of 
PDT and OxPt yields a superior therapeutic efficacy 
compared to each treatment alone, and both therapies 
harmonize to reduce inter-organoid heterogeneity and 
residual viable disease. Furthermore, the assessment of 
the prolonged effects of PDT and OxPt reveal a beneficial 
effect for the combination therapy to an extent that was 
not observed when treatment efficacies were evaluated at 
earlier timepoints, e.g., directly following OxPt exposure 
(day 10, Figure 3). These findings underscore the value 
of investigating treatment kinetics trough efficacy 
evaluations various time-intervals to fully grasp the scope 
of potential treatment effects.
PDT exerts delayed treatment effects in a 3D 
culture model of micrometastatic pancreatic 
cancer
The observation that PDT strongly reduced the 
extent of the viable disease following prolonged culturing 
post-treatment (day 18) when compared to the immediate 
response (day 8 and day 11) prompted the investigation 
towards the temporal  effects of PDT. The effects of PDT 
have classically been viewed as relatively immediate 
(24–48 h), where the short-lived reactive molecular 
species cause immediate oxidation of biomolecules, 
followed by direct necrosis or delayed cell death through 
apoptosis [36–41]. The observations in Figures 3 and 4 
indicate that in 3D cultures, the effects of PDT on these 
Figure 4: Effects of neoadjuvant PDT on prolonged OxPt dose response effects on AsPC-1 organoid cultures. OxPt 
treatment groups are depicted in blue, PDT+OxPt treatment groups are depicted in turquoise, and PDT treatment alone is depicted in 
purple. (A) Schematic overview of the experiment timeline. (B) Dose response curves based on the normalized organoid area (Mean ± 
stdev, N = 36). (C) Dose response curves based on the viability of the organoid cultures (Mean ± stdev, N = 36). (D) Dose response curves 
based on the cumulative viable area (Mean ± SEM, N = 9). Box-whisker plots depicting the medians, the 25th and 75th percentiles, and 
the 95% confidence interval of (E) the organoid viability (N = 36) and (F) the organoid live area per image (N = 36). (G) Scatter plots of 
organoid area and organoid viability following 500 µM OxPt (blue), 10 J/cm2 BPD-PDT (purple), and OxPt+PDT (turqoise). Significant 
size-response correlations are depicted in the image as determined using a Spearman’s ranked correlation test, displaying the Spearman 
coefficient r and the p-value for each data set (ns = no tsignificant). For each data set, the first 1000 nodules are displayed within a single 
representative experiment.
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3D cultures may be much more prolonged than generally 
assumed. We therefore investigated the temporal effects of 
PDT alone by examining the organoid cultures at varying 
time intervals following treatment (Figure 5A). 
Temporally spaced live/dead imaging following 
the PDT dose-escalation experiments reveal dramatic 
changes in the extent of viable disease of cultures 
analyzed on day 9 and 11 versus day 18 (Figure 5B). 
Again, organoid size (Figure 5C) did not differ between 
the PDT radiant exposure doses and analysis time-points. 
(Figure 5D) Analysis of viability revealed only slight 
dose-response correlations on day 9 (IC50 216 J/cm2) 
and day 11 (ambiguous IC50), yet the effects of PDT 
demonstrated effective dose-dependent organoid killing 
on day 18 (IC50 12 J/cm2). (Figure 5E) The residual 
viable disease followed a dose-response correlation 
immediately following PDT (Day 9), achieving a 
10% reduction in residual viable disease at a dose of 
10 J/cm2, justifying the use of this dose for the combination 
therapy experiments. However, the dose-response 
correlation was lost when cultures were analyzed on day 11, 
as the cultures appeared to have recovered from the 
initial treatment on day 8. Contrastingly, yet similar to the 
viability assessment, there was a strong dose-dependent 
reduction in viable disease on day 18. The IC50 for radiant 
exposure was significantly lower on day 18 (1 J/cm2) 
compared to day 9 (58 J/cm2), whereas no curve could be 
fitted for the day 11 analysis. PDT dose responses of the 
cultures on day 9 and 11 were not significantly different. 
In contrast, the responses measured on day 18 differed 
with high statistical significance from the responses 
measured on day 9 and 11 (Figure 5F, 5G), thus revealing 
delayed PDT responses in these 3D cultures.
DISCUSSION
It is generally accepted that combination treatments 
are needed for effective cancer therapy, FOLFIRINOX 
being an important example with respect to pancreatic 
cancer. These combinations are likely to be most effective 
when the therapeutic modalities have different modes 
of action and non-overlapping toxicity to healthy tissue. 
BPD-PDT constitutes a biophysical therapy that causes 
massive oxidative cellular damage and bypasses the 
barriers to apoptosis by direct destruction of mitochondrial 
membranes and release of cytochrome C [42]. As OxPt, 
part of FOLFIRINOX, achieves tumor destruction via DNA 
crosslinking [43], the combination of the mechanistically 
distinct PDT and OxPt constitutes a translationally relevant 
combination therapy for advanced pancreatic cancer. 
Therefore, this study investigated the adjuvant effects of 
PDT on the efficacy of OxPt chemotherapy. Our findings 
demonstrate decreased OxPt efficacy in a micrometastatic 
pancreatic cancer model compared to an equivalent model 
comprising cells from a primary tumor line. Neoadjuvant 
low-dose PDT significantly increased the efficacy of OxPt, 
which was further augmented in a time-dependent manner. 
These findings were mostly attributed to the delayed 
treatment effects of PDT on this model, relative to the 
time and dose-dependent effects of PDT and combinations 
observed in other models [13, 21, 39, 44]. 
The results of this study correlated well with 
previous findings on the BPD-PDT-susceptibility of 
PANC-1 organoids [27], and MIA PaCa-2 organoids 
[19]. Although the AsPC-1 organoids in the current study 
demonstrated substantial PDT-resistance in comparison 
to previous findings, these can be attributed to subtle 
differences in the experimental design [27] as it was 
previously demonstrated that variations in PDT dose 
parameters can have a great impact on the treatment 
outcomes [22, 39]. However, our findings on the effects 
of PDT on organoid cultures of PanCa contrasts with 
previous findings reported for ovarian cancer organoids. 
Whereas carboplatin diffusion and therapeutic efficacies 
were confined to the periphery of OVCAR-5 organoids 
[21], the OxPt effects were homogeneous throughout the 
AsPC-1 and MIA PaCa-2 nodules. Moreover, PDT was 
shown to disrupt ovarian cancer organoids leading to 
the disassociation of cancer cells from the nodules [21], 
whereas the effects of PDT on 3D culture of PanCa cells 
were confined to the periphery of the organoids. These 
discrepancies can be attributed to the different origins 
of the cell types and the distinct architectures of the 
organoids they form in 3D cultures. Such results highlight 
that cancer therapies have highly divergent mechanisms of 
action on different organotypic models of cancer.
The ability of PDT to enhance chemotherapy 
efficacies has been well-documented [21, 33, 44–46], 
and was shown to range from synergism to antagonism 
depending on the therapy sequence, cell lines, and 
photochemotherapy combination [20]. By employing a 3D 
model for micrometastatic ovarian cancer, we previously 
showed that pretreatment of the 3D cultures with BPD-
PDT synergistically enhanced carboplatin efficacy, 
whereas the reverse sequence (carboplatin first, then BPD-
PDT) did not [21]. Similar treatment effects were also 
observed in the current study (Supplementary Figure 3). 
Thus, the development of combinatorial regimens to 
improve overall response is not simply a matter of 
combining two mechanistically distinct therapies, and 
emphasizes the need for physiologically-relevant models 
to assess combinations. 
The beneficial effects of PDT on the OxPt efficacy 
likely stems from the distinct cytotoxic mechanisms of 
both therapies. PDT causes oxidation of vital biomolecules 
that culminates in the direct induction of apoptosis 
[47], and severely disrupts cellular redox homeostasis 
in surviving cells [7]. Subsequent OxPt-induced DNA 
damage may be more efficient as metabolism may be 
impaired and cells may perish through severe genomic 
instability combined with imbalanced redox homeostasis. 
Additionally, the multidrug transporter ABCG2 has been 
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shown to be downregulated following PDT in orthotopic 
in vivo models of pancreatic cancer, leading to increased 
irinotecan retention and therapeutic efficacy [9]. A recent 
investigation suggested that both mechanisms may be 
responsible for increased OxPt sensitivity of cancer cells 
following PDT, as was demonstrated on colorectal cancer 
cell lines (2D cultures) following hypericin PDT [48]. 
In addition, PDT is agnostic to the chemoresistant status 
of cells as gemcitabine-resistant pancreatic cancer cells 
retained sensitivity to PDT in 2D cultures [8]. Moreover, 
organotypic cultures of stable oxaliplatin-resistant 
pancreatic cancer cells exhibited altered 3D architecture 
and increased sensitivity to BPD-PDT relative to organoid 
cultures of the drug-naive cells [17]. 
The current study demonstrates the capacity of 3D 
cultures to comprehensively assess mesoscopic treatment 
effects that cannot be captured in 2D cell cultures or in 
in vivo models. As 3D cultures can be maintained for 
prolonged periods of time compared to 2D cultures, the 
organoid cultures enabled us to take temporal treatment 
Figure 5: Temporal- and radiant exposure-dependent effects of PDT on AsPC-1 organoid cultures as determined on 
day 9 (red), day 11 (dark red) and day 18 (purple). (A) Schematic overview of the experiment timeline. (B) Live/dead fluorescence 
overlays of the cultures following PDT at the indicated radiant exposures. Live cells are depicted in green, dead cells are shown in red. 
Scalebar = 400 µm. (C) Dose response curves based on the normalized organoid area (Mean ± stdev, N = 24–36). (D) Dose response 
curves based on the viability of the organoid cultures (Mean ± stdev, N = 24–36). (E) Dose response curves based on the cumulative viable 
area (Mean ± SEM, N = 6–9). Box-whisker plots depicting the medians, the 25th and 75th percentiles, and the 95% confidence interval of 
(F) the organoid viability per image (N = 24–36) and (G) the organoid live area per image (N = 24–36). 
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effects into consideration. Consequently, we identified 
unique treatment effects of PDT, OxPt, and the combined 
therapy on tumor architecture, and revealed a prolonged 
interaction between neoadjuvant PDT and OxPt on these 
cultures. The combined treatment was shown to overcome 
the limitations of both PDT (high residual heterogeneity 
and viability) and OxPt (high residual viable disease); the 
combination therapy PDT+OxPt yielded a homogeneously 
dispersed population of organoids with low viabilities and 
viable volumes. These findings highlight the importance 
of kinetic studies when evaluating combination therapies. 
Appropriate timing of treatment analysis is thus crucial to 
discern the full scope of possible treatment effects.
Although it is subject for further investigations, 
the results of this study provide a promising indication 
for PDT in the clinical management of advanced 
pancreatic cancer. The use of an ascites-derived cell line 
in an adherent 3D culture model bears resemblance to 
the adhesion of multicellular spheroids to the peritoneal 
wall or the mesothelial layers of various organs. This has 
particular significance for pancreatic cancer, as peritoneal 
invasion is frequently observed following surgery with 
curative intent. Survival rates for patients with peritoneal 
carcinomatosis are dismal, and procedures to prevent 
it are scarce [49]. Given the outcomes of the current 
investigation, a combined therapy of PDT and OxPt may 
hold potential to combat peritoneal pancreatic cancer 
metastases following surgery. A recent investigation 
demonstrated the utility of PDT for the treatment 
of micrometastatic ovarian cancer in vivo, using a 
photoimmunoconjugate composed of BPD and cetuximab 
and light-diffusing fiber tips for the complete irradiation 
of the abdominal cavity, achieving significantly reduced 
micrometastatic tumor burdens [49]. Intraperitoneal 
chemotherapy yields promising clinical outcomes for 
peritoneal carcinomatosis of various cancers [50–53]. 
The current investigation represents a preclinical model 
of peritoneal metastases of pancreatic cancer in which 
the combination of PDT with OxPt shows promise as a 
clinically feasible strategy to reduce metastatic burdens 
and prevent peritoneal carcinomatosis following surgery. 
A combination therapy of BPD-PDT and the 
FOLFIRINOX regimen may prove to be an efficient 
strategy for pancreatic cancer treatment. Within the 
FOLFIRINOX regimen, halting of DNA replication by 
irinotecan (topoisomerase inhibition) was shown to work 
in synergy with the DNA damaging therapies of folinic 
acid and 5-fluoruracil (base-substitution) and OxPt (DNA 
crosslinking) [1]. A critical aspect explaining the success 
of FOLFIRINOX is the relative absence of overlapping 
toxicities of its individual components, caused by the 
different molecular targets of each chemotherapeutic 
agent. In this respect, BPD-PDT is a suitable candidate for 
combination with FOLFIRINOX as it mainly targets the 
mitochondrial membranes [35], and thus lacks any overlap 
in toxicity profile with the chemotherapeutic agents. This 
study and others have demonstrated that PDT amplifies, 
and benefits from, the treatment effects of the individual 
components of the FOLFIRINOX regimen [9, 48, 54]. 
Lastly, the results of this study demonstrated that a 
combination therapy of PDT and OxPt overcomes the 
organoid size-dependent responses of each individual 
therapy. These findings warrant further exploration towards 
the beneficial effects of BPD-PDT in a neoadjuvant setting 
to the clinically employed regimen of FOLFIRINOX in 
mouse models of advanced pancreatic cancer. 
In conclusion, as single therapies typically fail 
to achieve satisfactory clinical outcomes for advanced 
pancreatic cancer, it is believed that a combination of 
therapies with distinct modes of action can provide better 
disease management without overlapping toxicities 
to healthy tissue. Both PDT and FOLFIRINOX have 
different mechanisms of action and show promising clinical 
results as individual therapies. The results from this study 
demonstrates that a combination of these therapies was 
significantly more effective compared to either therapy 
alone, using organoid models of pancreatic cancer cell 
lines of either metastatic or primary tumor origin. These 
findings demonstrate the promise of this combination 
therapy in the management of advanced pancreatic cancer. 
Neoadjuvant PDT may constitute a treatment option for 
surgery-ineligible patients regardless of performance 
score, given that lower chemotherapy doses could achieve 
effective disease management. As technical advancements 
pertaining to light administration throughout the abdominal 
cavity are underway, PDT may be employed as a post-
operative procedure to prevent peritoneal carcinomatosis 
following surgery, of which the current study provides 
promising preclinical evidence. The use of 3D models with 
computed analysis of treatment outcomes allows testing of 
large numbers of combinations, which are necessary for 
establishing the most effective set of treatment conditions. 
MATERIALS AND METHODS
Cell culture
Human pancreatic cancer cell lines MIA PaCa-2, 
PANC-1, and AsPC-1 were obtained from the American 
Type Culture Collection (ATCC, Manassas VA, obtained 
between 2010 and 2014). MIA PaCa-2 and PANC-1 cells 
were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM, Corning, Tewksbury MA) supplemented with 
10% (v/v) fetal bovine serum (Gibco, ThermoFisher, 
Waltham MA), 1% (v/v) penicillin/streptomycin (Corning). 
Cells were typically passaged weekly at 1:10 ratio. AsPC-1 
cells were cultured on Roswell Park Memorial Institute 
1640 (RPMI, Corning), supplemented with 10% (v/v) fetal 
bovine serum and 1% (v/v) penicillin/streptomycin. AsPC-1 
cultures were passaged weekly at a 1:8 ratio. Cells were 
used for experimentation between passages 5 and 30. Cells 
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tested negative for mycoplasma following completion of the 
study (Mycoalert plus, Lonza, Morristown NJ). 
To establish 3D adherent organoid cultures, AsPC-
1 or MIA PaCa-2 cells were seeded on solidified growth 
factor-reduced Matrigel (Corning) in black-walled 
24-wells plates (Sensoplate, Greiner Bio-One, Monroe, 
NC), at a density of 7500 cells/well (1 mL per well). 
Cultures were maintained in complete culture medium, 
additionally supplemented with 2% (v/v) growth-factor 
reduced Matrigel. Matrigel lot numbers used throughout 
this study were 5173009 and 36819 and contained 9.2 
mg/mL protein and <1.5 U/mL endotoxin. Culture media, 
supplemented with 2% Matrigel was refreshed every 
3–4 days.
Photodynamic therapy
The 3D cultures were subjected to PDT on culture 
day 8. Cultures were incubated with 0.25 µM BPD (Sigma 
Aldrich, St. Louis MO) in fresh culture medium for 90 min. 
Subsequently, the BPD-supplemented medium was 
replaced with fresh culture 2% Matrigel-containing 
medium and cultures were irradiated with 690 nm laser 
light (Intense, North Brunswick NJ), at a power density 
of 50 mW/cm2, and at total radiant exposures ranging 
between 1–50 J/cm2. Treatment effects were assessed on 
culture day 9, 11 and 18 as described below.
OxPt chemotherapy
The 3D cultures were treated with OxPt (Selleck 
Chemicals, Houston TX) on culture day 8 for a duration of 72 
h (to culture day 11). After OxPt incubation, cultures received 
fresh 2% Matrigel-containing medium devoid of OxPt until 
the termination of the experiments. Treatment effects were 
assessed on culture day 11 or 18 as described below. 
Quantitative assessment of culture growth and 
treatment effects
Organoids were stained in situ using 2 µM calcein 
AM (ThermoFisher) and 3 µM propidium iodide (PI, 
Sigma-Aldrich) for 30 min, after which the cultures 
were imaged on an Olympus FV1000 confocal laser 
scanning microscope at a 4× magnification, 4 µs pixel 
dwell time, and a resolution of 512 × 512 px. Calcein and 
PI fluorescence was detected at λexc= 488 nm and λem= 
520 ± 20 nm, and λexc= 559 nm and λem= 630 ± 20 nm, 
respectively. Images were subsequently analyzed using 
the CALYPSO methodology as described previously [19], 
applying a size threshold of 50 px (1925 µm2 or circa 6 
clustered cells). In every experiment, four consecutive 
non-overlapping images were taken per well, containing 
50–80 individual tumor organoids per image. Sizes, 
viabilities and viable organoid areas were determined 
for every individual tumor organoid, and the depicted 
data represents the median or average value per image as 
indicated. Cumulative viable disease was determined by 
summing the viable organoid areas per well (4 images/
well, 3 wells/experiment), and normalizing the values to 
the no treatment controls. 
Quantitative analysis of culture growth was 
performed using the CALYPSO methodology [19] without 
live/dead staining. Adaptive thresholding on the brightfield 
images was utilized to extract the sizes of individual tumor 
organoids at different time points. 
Statistical analysis
All statistical analyses were performed in Graphpad 
Prism 5.0 (La Jolla, CA). Data were tested for normality 
using the Pearson-Omnibus test. Non-Gaussian data 
were analyzed using either a Mann-Whitney U-test, or 
a Kruskal-Wallis and Dunn’s post-hoc test for multiple 
comparisons. Gaussian data were analyzed using either 
student’s t-test or a one-way ANOVA and Bonferroni post-
hoc test for multiple comparisons. Significance is indicated 
as either single asterisk (P < 0.05), double asterisk 
(P < 0.01), or triple asterisk (P < 0.005). Unless otherwise 
indicated, asterisks refer to significant difference between 
the control group and the designated group. Size-response 
correlations were calculated using a Spearman’s rank test.
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